Table 2 Demographics and baseline characteristics (n = 23 unless otherwise indicated)
Gender, n (%) | |
|---|---|
Female | 13 (56.5) |
Male | 10 (43.5) |
Age at diagnosis (years) [n = 21] | |
Mean (range) | 32.4 (10–58) |
Age at baseline (years) [n = 23] | |
Mean (range) | 46.5 (25–77) |
Weight at baseline (kg) | |
Mean (range) | 70.5 (50.3-94.9) |
Immunoglobulin trough level at baseline (g/L) | |
IgG mean (range) | 10.0 (3.3–13.1) |
IgA mean (range) | 0.19 (0.07–1.13) |
IgM mean (range) | 0.18 (0.04–1.17) |
Dosage per weight at baseline (mg/kg) | |
Mean (range) | 565.3 (441.0–714.3) |
Treatment product, n (%) | |
Gammagard® | 1 (4.4) |
Gamunex® | 14 (60.9) |
Privigen® | 6 (26.1) |
Octagam® | 2 (8.7) |
Primary immunodeficiency disease, n (%) | |
Common variable immunodeficiency | 22 (95.7) |
X-linked agammaglobulinemia | 1 (4.3) |